Related Experiment Video
Updated: Jun 3, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Pharmacologic activation of p53 by small-molecule MDM2 antagonists
1Department of Anatomy and Cell Biology Rush University Medical Center 1750 W Harrison Ave Jelke Building, Room 1306, USA.
Abstract:
Restoring p53 activity by inhibiting the interaction between p53 and MDM2 represents an attractive approach for cancer therapy. To this end, a number of small-molecule p53-MDM2 binding inhibitors have been developed during the past several years. Nutlin-3 is a potent and selective small-molecule MDM2 antagonist that has shown considerable promise in pre-clinical studies. This review will highlight recent advances in the development of small-molecule MDM2 antagonists as potential cancer therapeutics, with special emphasis on Nutlin-3.
Related Concept Videos
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway

